On January 6, 2011, Guzzo, Peter R.; Surman, Matthew David; Grabowski, James Francis, Jr.; Freeman, Emily Elizabeth published a patent.Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Preparation of azinone-substituted azepinoindole derivatives as MCH-1 receptor antagonists and use in the treatment of diseases. And the patent contained the following:
Title compounds I [A = CH, C, or N; B = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; L = (CH2)pO, (CH2)p, CH=CH, or bond; X = CR18, C(R18)2, N, or NR18; Y = CR18, C, or N; Z = CH, C, or N; R1 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc; R2 – R5 and R9 – R12 independently = H, halo, NH2 and derivatives, NHCO2H and derivatives, etc.; each R6 independently = H, halo, OH and derivatives, NH2 and derivatives, etc.; R7 = H, halo, NHCO2H and derivatives, (un)substituted aryl, heteroaryl, etc.; R8 = H, (un)substituted alkyl, cycloalkyl, heteroaryl, etc.; R13 and R14 independently = H, alkyl, haloalkyl, cycloalkyl, etc.; R18 = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc.; G = NR8CR9R10CR11R12, CR9R10NR8CR11R12, or CR9R10CR11R12NR8; provided that when G = CR9R10NR8CR11R12, R2 and R3 are not CONR13R14; n = 0 to 3; p = 1 to 4; dash bond represents an optional double bound], and their pharmaceutically acceptable salts, oxides, solvates, or prodrugs, are prepared and disclosed as MCH-1 receptor antagonists and useful in the treatment of obesity, anxiety, depression, non-alc. fatty liver disease, and psychiatric disorders. Thus, e.g., II·2HCl was prepared by cross-coupling of 2-bromo-5-trifluoromethylpyridine with 2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine followed by demethylation, arylation with tert-Bu 8-bromo-6-methyl-1,2,4,5-tetrahydroazepino[4,5-b]indole-3(6H)-carboxylate, hydrolysis, and addition of hydrochloric acid. Select I were evaluated for their MCH-1 antagonistic activity, e.g., II·2HCl demonstrated a Ki value of 10.1 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol
The Article related to azinone azepinoindole derivative preparation mch receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Quality Control of (6-(Trifluoromethyl)pyridin-3-yl)methanol
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts